KNSA Kiniksa Pharmaceuticals Interna
$95.18▲ +6.70%
Healthcare
Other
After hours
$94.32▼ -0.90%
Oct 28, 5:09 PM ET
Volume 1.70M
Avg Volume (10D) 1.00M
Key Metrics & Fundamentals
Market Cap
$7.43B
P/E Ratio
72.1
Div Yield
0.00%
52W Range
36.56 - 95.28
% vs 50 MA
21.18%
% vs 200 MA
59.57%
RSI-14
70.2
MACD Histogram
+1.1900
Beta (1Y vs SPY)
0.31
Free Cash Flow
$46.53M
Gross Rev
$243.60M
Gross Profit
$131.96M
EBITDA
$27.67M
COGS
$111.64M
Operating Exp
$104.77M
Operating Income
$27.19M
EBIT
$27.19M
Pretax Income
$31.15M
Net Income
$25.43M
EPS (Diluted)
0.30
Price & Volume History
Loading chart…
Recent News
Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
Simply Wall St. · Oct 28, 2026 3:11 AM ET
Kiniksa Pharmaceuticals International PLC (KNSA) (Q3 2026) Earnings Call Highlights: ARCALYST ...
GuruFocus.com · Oct 27, 2026 9:03 PM ET
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Motley Fool · Oct 27, 2026 2:11 PM ET
Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary
Moby · Oct 27, 2026 1:53 PM ET
Top Midday Gainers
MT Newswires · Oct 27, 2026 1:37 PM ET
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
Motley Fool · Oct 27, 2026 12:43 PM ET
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
MarketBeat · Oct 27, 2026 12:04 PM ET
Wedbush Adjusts PT on Kiniksa Pharmaceuticals International to $102 From $99, Maintains Outperform Rating
MT Newswires · Oct 27, 2026 10:54 AM ET
Kiniksa Pharmaceuticals' Q3 Net Income, Revenue Rise; Shares Up Pre-Bell
MT Newswires · Oct 27, 2026 8:10 AM ET
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Zacks · Oct 27, 2026 7:50 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See KNSA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.